ConductScience.org, home

Comparison · NCT05894577-sae

Arm F - Montelukast vs Arm F - Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm F - Montelukast vs Arm F - Placebo: serious adverse events. Trial comparisons, record NCT05894577-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05894577-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.009550.004390.0207wilson
Risk in group 20.004820.001640.0141wilson
Risk difference, group 1 minus group 20.00473-0.005870.0163newcombe hybrid score
Risk ratio, group 1 over group 21.980.4987.89log
Odds ratio, group 1 over group 21.990.4967.99log
Number needed to harm, for one more participant with a serious adverse event on Arm F - Montelukast than on Arm F - Placebo211from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm F - Montelukast
Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.~Montelukast: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
6628EG000
Group 2Arm F - Placebo
Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing.~Placebo: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
3622EG001

Harm

What it counts
Total, serious adverse events
Time frame
Up to 180 days

Source ClinicalTrials.gov

Trial

Title
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
NCT number
NCT05894577
Phases
PHASE3
Conditions
Covid19
Interventions
Placebo, Montelukast
Lead sponsor
Susanna Naggie, MD
Results first posted
2024-08-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05894577-sae